Insiders Trades
LNA Sante Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 29 Jun 2026.
LNA Sante: what insiders have been doing
This page follows insider dealings at LNA Sante as filed with AMF, a company from the Healthcare & Pharma sector based in France. The group dates from 1992. In the past year (18 October 2025 to 18 October 2026), 12 filings came from 4 insiders.
Not one open-market sale was filed. On the buying side, 2 insiders reported 9 purchases totalling €7.2M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 2 board members. The largest single trade was a purchase of €3.5M by Financiere Vertavienne 44 SAS, published on 13 April 2026.
For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 12 filings here. Over the whole record (from 2021), the tally stands at 115 purchases and 7 sales.
In all, 3 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 29 June 2026, 110 days ago. Filings reach the AMF feed a median of 6 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Source: insider filings from AMF. Past trades are no guide to future returns.
Key facts
Headquarters: France · Founded: 1992
Source: Wikidata (CC0).
Insider Decl.
139
Thresholds
n/a
Buy Volume
€51M
115 ops. · all time
Sell Volume
€13M
7 ops. · all time
Who traded when
BuySaleJean-Paul Siret9 buys
Willy Siret2 buys1 sale
Financiere Vertavienne 44 SAS1 buy
Since the insiders bought
- -33.0%Entry €35.20 · Close 14 Oct 2026 €23.60
- -18.6%Entry €29.00 · Close 14 Oct 2026 €23.60
- +1.7%Entry €23.30 · Close at T+365 €23.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 4,226 of 24,148 companies
68.3
score / 100
Value86
Quality51
FCF yld36%
Earn yld10%
EV/EBITDA7.5x
ROE8.0%
Gross mgn88%
Net mgn2.6%
Debt/EBITDA5.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€23.60
Analyst consensus
4 analysts1.50/5
€36.00Target €41.10(+74%)€47.00
Income statement
Revenue€912.7M
Gross profit€801.0M88% margin
EBITDA€153.7M17% margin
Net income€24.1M2.7% margin
Valuation
PER (trailing)9.6x
PER (forward)6.9x
P/Book0.7x
Beta0.52
Balance sheet & cash
Market cap€243.0M
Total debt€906.4M
Free Cash Flow€86.4M
Debt / Equity274%
Profitability & ownership
ROE8.0%
ROA2.9%
% insiders55.2%
% institutions11.2%
Last declaration on 29 June 2026
Declarations139 total
769 shares@ €32.900.0072% mcap0.1% of flowActionEuronext ParisISIN FR00041700172026DD1123327
Canonical exit: 21 Sept 2026 (T+90)
651 shares@ €32.9940.0063% mcap0.1% of flowActionEuronext ParisISIN FR00041700172026DD1122318
Canonical exit: 16 Sept 2026 (T+90)
200 shares@ €33.000.0019% mcap0.0% of flowActionEuronext ParisISIN FR00041700172026DD1121513
Canonical exit: 10 Sept 2026 (T+90)
1,449 shares@ €33.000.014% mcap0.2% of flowActionEuronext ParisISIN FR00041700172026DD1119817
Canonical exit: 2 Sept 2026 (T+90)
856 shares@ €29.500.0083% mcap0.1% of flowActionEuronext ParisISIN FR00041700172026DD1115357
Canonical exit: 12 Aug 2026 (T+90)
233 shares@ €28.000.0020% mcap0.0% of flowActionEuronext ParisISIN FR00041700172026DD1111804
Canonical exit: 6 Jul 2026 (T+90)
2,410 shares@ €28.99540.021% mcap0.3% of flowActionEuronext ParisISIN FR00041700172026DD1110273
Canonical exit: 20 Jul 2026 (T+90)
132,373 shares@ €26.354100.0% of flowActionEuronext ParisISIN FR00041700172026DD1107254
Canonical exit: 6 Jul 2026 (T+90)
132,123 shares@ €26.35114.4% of flowActionEuronext ParisISIN FR00041700172026DD1105359
Canonical exit: 25 Jun 2026 (T+90)
4,333 shares0ActionEuronext ParisISIN FR00041700172026DD1092851
4,333 shares0ActionEuronext ParisISIN FR00041700172026DD1092855
4,333 shares0ActionEuronext ParisISIN FR00041700172026DD1092857
3,450 shares@ €29.0032.5% of flowActionEuronext ParisISIN FR00041700172025DD1059134
Canonical exit: 18 Dec 2025 (T+90)
3,450 shares@ €29.0021.7% of flowActionEuronext ParisISIN FR00041700172025DD1059139
4,166 shares0ActionEuronext ParisISIN FR00041700172025DD1013158
4,166 shares0ActionEuronext ParisISIN FR00041700172025DD1013142
4,166 shares0ActionEuronext ParisISIN FR00041700172025DD1013155
10 shares@ €22.600.0% of flowActionEuronext ParisISIN FR00041700172024DD1011790
Canonical exit: 17 Mar 2025 (T+90)
3,993 shares@ €23.99139.1% of flowActionEuronext ParisISIN FR00041700172024DD1002198
Canonical exit: 20 Jan 2025 (T+90)
6,492 shares@ €23.811814.6% of flowActionEuronext ParisISIN FR00041700172024DD1001667
Canonical exit: 15 Jan 2025 (T+90)
399 shares@ €23.82780.9% of flowActionEuronext ParisISIN FR00041700172024DD1000962
Canonical exit: 12 Jan 2025 (T+90)
24 shares@ €22.600.1% of flowActionEuronext ParisISIN FR00041700172024DD1000305
Canonical exit: 7 Jan 2025 (T+90)
102 shares@ €22.82840.2% of flowActionEuronext ParisISIN FR00041700172024DD999778
Canonical exit: 2 Jan 2025 (T+90)
2,000 shares@ €23.104.4% of flowActionEuronext ParisISIN FR00041700172024DD999287
Canonical exit: 31 Dec 2024 (T+90)
804 shares@ €23.00661.7% of flowActionEuronext ParisISIN FR00041700172024DD997412
Canonical exit: 22 Dec 2024 (T+90)
25 of 139 declarations
About LNA Sante
LNA Santé is a French healthcare operator focused on supporting frail and dependent people, especially elderly patients and residents who require long-term care, rehabilitation or more complex medical support. Listed on the market under ISIN FR0004170017, the group was historically known as Le Noble Age before rebranding as LNA Santé in 2016 to better reflect its role as a broader healthcare platform spanning both medico-social and clinical activities. The company was founded in Nantes in 1990 by Jean-Paul Siret, who remains its Chairman and founder. Its growth started with a pioneering nursing home, La Chézalière, and then with early facilities dedicated to Alzheimer’s disease, before extending into the healthcare segment at the end of the 1990s.
Today, LNA Santé operates a diversified portfolio of healthcare businesses. Its main activities include nursing homes and assisted living facilities, post-acute and rehabilitation clinics, surgical clinics, home hospitalization, mental health care and other local healthcare services. This multi-activity model allows the group to cover a wide range of patient needs across the care pathway, from accommodation and daily support to clinical treatment, rehabilitation and home-based care. The group emphasizes a human-centered model built around hospitality quality, professional caregiving, operational proximity, innovation and personalized care plans.
Read moreShow less
As of 2025, LNA Santé reported 87 establishments, around 9,500 professionals and €878 million in operating revenue. It is therefore a meaningful independent player in the French healthcare landscape, although still smaller than the largest consolidated groups in the sector. Independence is a defining feature of the company’s strategy and governance. LNA Santé highlights its family ownership structure, controlled shareholding base and the increased involvement of employees, who collectively own 10% of the share capital.
Geographically, the group is primarily concentrated in France, with an established presence in Belgium as well. This selective footprint is consistent with its operating model and its desire to deepen expertise rather than pursue uncontrolled expansion. LNA Santé also stands out for its long-term strategic orientation: it has become a mission-driven company and has reinforced commitments linked to social, societal and environmental performance. Among the company’s notable features are its steady expansion since inception, its recognized expertise in Alzheimer’s care, and its gradual shift toward higher-value healthcare activities with stronger medical intensity.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
